Skip to main content

Opioids for C diff Pain Connected to Worse Outcomes

      

ORLANDO — For patients infected with Clostridium difficile, significant opioid use appears to be associated with increases in the severity of infection and in-hospital mortality, new research suggests.
"As physicians, when we see someone in pain, we often will default to opioids. This study raises awareness that, in C difficile patients in particular, opioids should be avoided," said Elizabeth John, MD, from Rutgers University in New Brunswick, New Jersey.
Opioid use has not been typically associated with C difficile infection. However, in a preliminary study, Dr John and her colleagues found an association between opioid use, longer hospital stays, and higher white blood cell counts in infected patients (Gastroenterology. 2017;5[Suppl 1]:S347).
In a follow-up study, which Dr John presented here at the World Congress of Gastroenterology 2017, the researchers reviewed the medical records of 302 adults with clinically diagnosed C difficile infection. All patients were hospitalized for a minimum of 3 days.
Patients who were dispensed a morphine-equivalent dose of an opioid of at least 10 mg during their hospital stay were assigned to the opioid group. All other patients served as the control group. Regression analyses controlled for the previous use of antibiotics, the use of acid suppressive medication, the source of infection (hospital vs community), comorbidities, and demographic characteristics.
Severe or complicated C difficile infection was more common in the opioid group than in the control group. And the rate of complicated infection alone was higher in the opioid group.
Average hospital stay was longer in the opioid group than in the control group (25 vs 15 days; adjusted incidence rate ratio, 1.46; P = .03). And the in-hospital mortality rate was higher in the opioid group.
Now I know we are on to something.
"I was surprised by how strong the findings were," Dr John told Medscape Medical News. "They make sense to me, but after seeing them validated in a large sample population, now I know we are on to something."
Because opioids are known to slow the gastrointestinal tract, they might increase the absorption of C difficile bacterial toxins, she suggested.
"Given the opioid abuse epidemic, this study highlights another reason for patients and their healthcare providers to carefully consider alternative agents to opioids," Keith Obstein, MD, from Vanderbilt University in Nashville, Tennessee, said when asked to comment by Medscape Medical News.
Dr John and Dr Obstein have disclosed no relevant financial relationships.
World Congress of Gastroenterology 2017: Poster P103. Presented October 15, 2017.
Follow Medscape Gastroenterology on Twitter @MedscapeGastro and Damian McNamara @MedReporter

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more